Medigen Vaccine Biologics Corporation (TPEX:6547)

Market Cap	17.92B +4.6%
Revenue (ttm)	613.17M +1.2%
Net Income	-281.71M
EPS	-0.86
Shares Out	328.75M
PE Ratio	n/a
Forward PE	143.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,718,720
Average Volume	2,185,370
Open	49.60
Previous Close	49.60
Day's Range	49.50 - 54.50
52-Week Range	33.50 - 59.90
Beta	0.79
RSI	86.77
Earnings Date	May 15, 2026

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respirat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 103
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6547

Financial Performance

In 2025, Medigen Vaccine Biologics's revenue was 613.17 million, an increase of 1.24% compared to the previous year's 605.64 million. Losses were -281.71 million, 250.1% more than in 2024.